Monte Rosa Therapeutics announced that its management team will host a live conference call and webcast on Wednesday, January 7 at 8:00 a.m. ET to unveil interim clinical data from the ongoing Phase 1 study of MRT-8102, a NEK7-directed molecular glue degrader. Investors can access the webcast via the “Events & Presentations” section of the company’s investor website; registration is open now and an archived replay will remain available for 30 days following the presentation.

In the Part 3 cohort—designed as a proof-of-concept in subjects with elevated cardiovascular risk—12 patients across three dose levels (10 mg, 30 mg and 60 mg once-daily) have been treated for up to 28 days. Preliminary analysis shows a mean high-sensitivity C-reactive protein (hs-CRP) reduction of 48% from baseline at day 28 in the 60 mg group, with 4 of 6 subjects achieving hs-CRP levels below 2 mg/L. Across all cohorts, MRT-8102 was well tolerated, with no dose-limiting toxicities or grade 3 adverse events reported to date. These results support dose escalation into the planned 100 mg cohort and inform the design of upcoming proof-of-efficacy studies.